Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

- 1. (Currently amended) A method for transducing a gene into <u>non-immortalized</u> T cells, wherein said method comprises the step of contacting a paramyxovirus vector carrying the gene with activated <u>non-immortalized</u> T cells.
- 2. (Original) The method according to claim 1, wherein the paramyxovirus vector is a Sendai virus vector.
 - 3-7. (Cancelled)
 - 8. (New) The method according to claim 1, wherein the T cells are CD8+ T cells.
- 9. (New) The method according to claim 1, wherein the activated T cells are antigen-activated T cells.
 - 10. (New) The method according to claim 9, wherein the antigen is an alloantigen.

- 11. (New) The method according to claim 9, comprising a step of stimulating T cells with an antigen.
- 12. (New) The method according to claim 11, wherein the antigen is an alloantigen.
- 13. (New) The method according to claim 9, further comprising a step of stimulating T cells with anti-CD3 antibody and anti-CD28 antibody.
- 14. (New) A non-immortalized T cell transduced with a foreign gene prepared by the method according to claim 1.
- 15. (New) The method according to claim 1, wherein the contact is done with coexistence of naive T cells and activated T cells, thereby transducing a gene into activated T cells with higher efficiency than naive T cells.
- 16. (New) A cell mixture prepared by the method according to claim 15, comprising activated non-immortalized T cells transduced with a foreign gene and naive T cells.

- 17. (New) A method of enhancing paramyxovirus vector-mediated gene transduction efficiency in non-immortalized T cells, wherein the method comprises the step of activating non-immortalized T cells before contacting the paramyxovirus vector.
- 18. (New) The method according to claim 17, wherein the T cells are CD8+ T cells.
- 19. (New) The method according to claim 17, wherein the T cells are antigenactivated.
- 20. (New) The method according to claim 19, wherein the antigen is an alloantigen.
- 21. (New) The method according to claim 19, further comprising a step of stimulating T cells with anti-CD3 antibody and anti-CD28 antibody.